SlideShare a Scribd company logo
1 of 100
Download to read offline
IMPORTANT TRIALS IN GLAUCOMA
Presenter-Dr Ravneet
Moderator- Dr Hetal Shah
Dr Rita Dhamankar
Dr Vijay Shetty
Landmark studies in glaucoma
 Ocular Hypertension Treatment study (OHTS)
 Collaborative Initial Glaucoma treatment Study (CIGTS)
 Advanced Glaucoma Intervention Study (AGIS)
 Early Manifest Glaucoma trial (EMGT)
 Collaborative Normal Tension Glaucoma (CNTGS)
 Tube versus Trabeculectomy study (TVT)
 European Glaucoma prevention study(EGPS)
 Low Tension Glaucoma prevention Study(LoGTS)
Ocular Hypertension Treatment
study (OHTS)
3
Arch Ophthalmol 120: 701-713, 2002.
Ocular Hypertension Treatment study (OHTS)
Objective:
 To evaluate the safety and efficacy of topical ocular
hypotensive medications in preventing or delaying onset
of visual field loss and or optic nerve damage in subjects
with ocular hypertension.
 Identify baseline demographic and clinical factors that
predict which participants will develop POAG
4
Ocular Hypertension Treatment study (OHTS)
Participants:
 1637 patients with ocular hypertension recruited
between 1994 and 1996
Study design:
 Multicentre randomized controlled clinical trial
comparing observation with medical therapy for
ocular hypertension.
5
Methods:
 1637 participants
 no evidence of glaucomatous damage,
 40 to 80 years
 IOP 24 mmHg - 32 mmHg in one eye
21mmHg and 32 mmHg in other eye
 The goal in the medication group was to reduce the IOP
by 20% or more and to reach an IOP of 24 mmHg or less.
Ocular Hypertension Treatment study (OHTS)
OHTS Phase 1
Begins February 28, 1994
Eligibility Criteria
Medication
Topical treatment to lower IOP 20%
and IOP < 24 mm Hg
Observation
No topical treatment to lower IOP
Randomization
Reproducible Abnormality
3 consecutive visual fields and/or 2 consecutive sets of optic disc photographs
Monitoring
Humphrey 30-2 q6 months
Stereoscopic disc photos annually
POAG
Visual field and/or optic disc changes attributed to
POAG
Adjust therapy if
target not met
Ocular Hypertension Treatment study (OHTS)
Results :
At 5 years followup
 Incidence of POAG
9.5% in controls
4.4% in treatment group
 22.5% decrease in IOP in the treatment group
8
OHTS Summary of results
CCT < 555 & IOP > 25 CCT < 555 & CD > 0.5
Risk 36% Risk 22%
CCT > 588 &IOP > 25 CCT > 588 & CD >0.5
Risk 6% Risk 8%
Ocular Hypertension Treatment study (OHTS)
Increased risk of the onset of POAG was associated
with:
 Increased age
 Vertical and horizontal cup disc ratio
 Pattern standard deviation
 IOP at baseline
 Central corneal thickness (CCT) was found to be a
powerful predictor for the development of POAG.
Ocular Hypertension Treatment study (OHTS)
 The corneas in OHTS subjects were thicker
 lower corneal thickness in black subjects than
whites.
 The effect of CCT may influence the accuracy of
applanation tonometry in the diagnosis, screening
and management of patients with glaucoma and
ocular hypertension.
1
2
Clinical useful points from OHTS
 OHT – What to do
* Treat all
* Treat no one
* Treat some
-- Is treatment effective
DOES OHTS HAVE ANSWERS FOR THIS
Clinical useful points from OHTS
 Treat only patients at high risk.
 Risk factors – risk calculator
www.discoveriesinsight.org
 Importance of CCT
 ONH & VF monitoring at every FU
 Study – Rx effective , of the 9.6% that
converted half could be prevented by Rx
 OHTS - ? Conversion after longer FU
Age Vertical
C/D
IOP DM+
CCT PSD
If not high risk waiting to treat OHT till
conversion- better strategy ( vision related
QOL)
OHTS PHASE2
March
OHTS Phase 2
Medication Group
N = 694
Medication is continued
in the Medication group
OHTS Phase 2
N = 672
Medication is Initiated
in the Observation group
OHTS Phase 2: Rationale
 OHTS Phase 1 provides proof of concept:
medication reduces the incidence of POAG.
 OHTS Phase 1 does not indicate when
medication should begin.
 OHTS Phase 1 does not indicate if all OHT
patients should receive early medication.
OHTS Phase 2: Methods
After 7.5 years of observation, participants originally
randomized to observation group start medication.
This creates:
Delayed treatment group
Observation group followed for 7.5 years then treated for 5.5 years
Early treatment group
Medication group treated for median of 13 years from the beginning
Compare incidence of POAG at 13.0 years
OHTS PHASE 2 RESULTS
 Median Time to develop POAG:
Observation group-6 yrs
Medication group-8.7 yrs
 Increased cumulative incidence of POAG at 13 yrs
(22% vs 16%)
 More eyes with structural and functional damage(8%
vs 5%)
 More participants with bilateral disease (6% vs 4%)
Ocular Hypertension Treatment study (OHTS)
 The primary purpose of the follow up study was to
determine whether delaying treatment resulted in
persistently increased risk of conversion to
glaucoma, even after the initiation of therapy.
2
0
Ocular Hypertension Treatment study (OHTS)
Implications:
 Ocular hypertensives can be seperated into
categories of high,medium & low risk.
 People with high risk factors may benefit from
close followup and early treatment
 Low risk patients can have less frequent followup
and may not need early treatment.
2
1
Ocular Hypertension Treatment study (OHTS
 Subjects with corneal thickness of 555μm or less had
three times the risk of developing primary open-angle
glaucoma compared with those who had corneal
thickness of 588μm or more.
 Therefore, measure central corneal thickness of all
new glaucoma suspects.
Early Manifest Glaucoma trial
(EMGT)
2
4
Early Manifest Glaucoma trial (EMGT)
Purpose:
 To compare the effect of immediate therapy to lower
the intraocular pressure versus late or no treatment
on the progression of newly detected open-angle
glaucoma,as measured by increasing visual field loss
and or optic disc changes
2
5
Early Manifest Glaucoma trial (EMGT)
Participants:
 Newly diagnosed POAG patients (255)
 50 to 80 years of age
 255 patients were randomized between 1993
and 1997.
2
6
Early Manifest Glaucoma trial
(EMGT)
Study design:
 Multicenter randomized controlled clinical trial
comparing observation with betaxolol and argon
laser trabeculoplasty for OAG.
2
7
EMGT
• Randomised to
-ALT and betaxolol
-No treatment
• If IOP >25mmHg in treated (>35 untreated)
→ Latanoprost added
• If remains high
→ individualised treatment
Early Manifest Glaucoma trial (EMGT)
Results:
 At 6 years, 62% of untreated patients showed
progression, whereas 45% of treated patients progressed.
Treatment reduced IOP by 25%.
 Median time to progression 66 months in treated versus
48 months in untreated .
2
9
EMGTS – results
 Progression
 62% - control
 45% - treated group
 25% IOP - risk of
progression by 50%
 Risk of progression less
with larger initial IOP
drop
 Risk of progression by
10% / mm Hg IOP from
baseline
Early Manifest Glaucoma trial (EMGT)
 In the control group , the rate of visual field
progression was fastest in the subgroup of
patients with exfoliation and slowest in those
with normal IOPs at baseline.
3
1
Early Manifest Glaucoma trial (EMGT)
Baseline risk factors:
 Higher IOP
 Exfoliation
 Older age
 Lower systolic perfusion pressure
 Lower CCT among patients with higher IOPs
 follow up higher IOP,
 disc hemorrhages.
3
2
Early Manifest Glaucoma trial (EMGT)
Implications:
 In eyes with glaucoma ,IOP that was lowered by
an average of 25%, treatment was of benefit
versus no treatment .
 There is beneficial effect of immediate therapy to
lower the intraocular pressure versus late or no
treatment on the progression of newly detected
OAG
3
3
Clinical Implications
 Even small reductions in IOP can make a difference.
 Every 1mm of IOP reduction was associated with a
risk reduction of 10% to 13%, depending on the
analysis,
 But that doesn't necessarily mean all patients must be
treated, because we can't know which patients will
progress, in some cases, we can observe closely and
tailor management to the individual patient
 It's beneficial to lower pressure in patients
progressing quickly, even if IOP levels have been in
the range of 15 to 18mm Hg,
Clinical useful points from EMGTS
 25% IOP - progression from 62 – 45%
 Regular FU every 3 – 6 months with ONH & VF
must – not commonly practiced.
 Pts with low risk of progression left untreated –
no effect on QOL till lifetime
 Drawbacks – Rx options limited – better drugs
now
Collaborative Initial Glaucoma
treatment Study (CIGTS)
Am J Ophthalmol 1998;126:498-505
Collaborative Initial Glaucoma treatment Study (CIGTS)
Purpose:
 To determine whether patients with newly
diagnosed open angle glaucoma (OAG) are better
treated by initial treatment with medications or
by immediate filtering surgery.
 In addition, a secondary measure—a health-
related quality of life questionnaire—looked at
how the treatment affected the patient's lifestyle.3
9
Collaborative Initial Glaucoma treatment Study
(CIGTS)
Participants:
 607 patients with OAG ( primary, pigmentary, or
pseudoexfoliative) recruited between 1993 and 1997.
Study design:
 Multicenter randomized controlled clinical trial
comparing initial medical with initial surgical
therapy for OAG.
4
0
 First time the concept of Target IOP was used.
March
CIGTS
MEDICATION GROUP
N = 307
SURGICAL GROUP
N = 300
CIGTS
 RESULTS
 At 5 yrs both effective
 Control of IOP lower by
surgery (48%), medical
(35%)
 VF loss greater in
surgery (cataract)
 QOL initially better
with medical group
CIGTS – Results at 5yrs
Medical
Treatment
Surgical
Treatment
IOP reduction 28mmHg→17-18mmHg
(38%)
27mmHg→14-15mmHg
(46%)
Progression at 5 years No progression No progression
• Surgical group is at increased risk of visual loss initially
but by 4yrs both groups are comparable
•The rate of cataract removal was greater in the surgically
treated group.
Collaborative Initial Glaucoma treatment Study (CIGTS)
Results
 Patients with diabetes were more likely to
progress if treated with surgery first.
 The quality of life (QOL) impact reported by the
2 treatment groups was very similar.
 Increased impact of local eye symptoms reported
by the surgery group
4
5
Collaborative Initial Glaucoma treatment Study (CIGTS)
Results
 The overall rate of progression of OAG in CIGTS
was lower than in many clinical trials, potentially
the result of more aggressive IOP goals and the
stage of the disease.
CIGTS summary
 Surgery resulted in
 Lower IOP
 More cataract
 More ocular side effects
 Initial ↓ vision
 Initial ↓ visual field
Collaborative Initial Glaucoma treatment Study
(CIGTS)
Implications
 In moderate to advanced disease initial surgical
therapy may be preferred.
 The results also revealed that either treatment had a
remarkably similar effect on patients' quality of life.
 Though not associated with a particular treatment
group, the fear of blindness was common, affecting
34% at diagnosis.
 Patients who reported a decrease in visual
functioning were more likely to experience depression
and mood changes
4
8
Clinical useful points from CIGTS
 Early POAG – medical Rx effective
 Our scenario – compliance/cost – deciding factor for
either modality
 Concept of target IOP – must in our management.
 Drawback – study duration too short for Rx
recommendation.
Advanced Glaucoma
Intervention Study (AGIS)
5
1
Advanced Glaucoma Intervention Study (AGIS)
Purpose:
To compare the clinical outcomes of 2 treatment
sequences in cases of advanced glaucoma
5
2
Advanced glaucoma intervention
study (AGIS)
 Objective – to determine if ALT or surgery is
preferred Rx for advanced glaucoma on max
tolerated medical Rx.
789 eyes
ALT
TRAB
TRAB
(ATT)
TRAB
ALT
TRAB
(TAT)
Advanced Glaucoma Intervention Study (AGIS)
Participants:
 789 eyes of 591 patients with medically
uncontrolled OAG recruited from 1988 to 1992.
 POAG uncontrolled on maximum accepted and
tolerated medical therapy(IOP ≥ 18 mm Hg)
 35 to 80 yr
5
4
Advanced Glaucoma Intervention Study (AGIS)
Study design:
 Multicenter randomized controlled clinical trial
comparing 2 treatment sequences (TAT and ATT ) for
patients with OAG uncontrolled by medical therapy.
Advanced Glaucoma Intervention Study (AGIS)
Results:
 Black patients had less combined visual acuity and visual
field loss if treated with the ATT sequence.
 White patients had less combined visual acuity and visual
field loss at 7 years if treated with the TAT sequence.
 Visual function scores improved after cataract surgery.
5
6
AGIS - Results
 Relationship of IOP & VF progression.
 Predictive analysis – IOP < 14 mm Hg did better
 Associative analysis – low IOP & low IOP
fluctuation - Decreased progression
Advanced Glaucoma Intervention Study (AGIS
Results:
 Lower IOP was associated with less visual field loss.
 First 18 months after the first surgical intervention, or
eyes with IOP of 18mmHg or less at all visits throughout
the study had significantly less visual field loss
 Approximately half of the study patients developed
cataract in the first 5 years of follow up.
 Trabeculectomy increases the relative risk of cataract
formation by 78%.
5
8
Advanced Glaucoma Intervention Study (AGIS)
Results
 ALT failure is associated with
-younger age
-higher IOP.
 Trabeculectomy failure associated with
-younger age,
-higher IOP,
-diabetes, and postoperative complications such as particularly elevated
IOP and marked inflammation.
-IOP fluctuation was an independent predictor of progression of OAG in
eye with lower baseline IOPs.
Results - AGIS
 TAT
 IOP
 Better for whites
 ATT
 Failure
 Better for blacks
Risk of cataract after TRAB after 5 years – 78 %
AGIS
 Effects of IOP on visual field progression were also
specifically evaluated from AGIS data, and it was
found that patients with an average IOP of greater
than 17.5mm Hg had greater worsening of their visual
fields than those with an average IOP of less than
14mm Hg.
 AGIS was one of the first studies to show that lower
mean IOP results in a decreased risk of visual field
progression.
AGIS
 Each patient requires individualized care.
 AGIS demonstrated that race is an important
consideration for surgical intervention in advanced
glaucoma.
 This is not to say, for instance, that a white patient
with medically-uncontrolled glaucoma should only be
offered the option of trabeculectomy.
 Potential operative complications associated with the
more invasive surgery may sway the patient toward
laser intervention as a first option.
AGIS
 Conversely, a black patient presented with the option
of laser intervention should be warned of the likely
future need for both additional medications and
additional glaucoma surgery after the laser procedure
is completed.
AGIS
 There is no magic number for target IOP.
 Patients in the AGIS group who consistently
maintained IOP less than 18mm Hg at every visit over
six years, with mean IOP of 12.3mm Hg as a group,
had good preservation of visual field—yet a number of
patients in this group still showed progressive visual
field loss.
Advanced Glaucoma Intervention Study (AGIS)
Implications:
 Keep race in mind when choosing therapy.
 Lower IOP was associated with less visual field loss
 IOP fluctuation was an independent predictor of
progression of OAG in eye with lower baseline IOPs.
6
5
Collaborative Normal Tension
Glaucoma (CNTGS)
6
6
 Lowering IOP in patients with normal-tension
glaucoma (NTG) can be challenging.
 Is it even worth trying to lower an already-low IOP?
Collaborative Normal Tension Glaucoma (CNTGS)
Purpose:
 To determine if IOP plays a part in the pathogenic
process of NTG by comparing a treatment group (with
a 30% reduction in IOP) to a no treatment group. .
6
8
Collaborative Normal Tension Glaucoma (CNTGS)
Participants :
 230 patients
 20-90 yrs
 Patients had unilateral or bilateral NTG
 Three reliable visual fields within 1 month
 Average IOP ≤20 mmHg,no reading above 24 mmHg
6
9
NTGS - methods
 Randomised immediately if
 VF defect threatening fixation
 Previously documented disease progression
 Others randomised when evidence of progression
NTGS
 145 (of 239) patients randomised
 One eye randomised to
 Treatment
 Drops, ALT or surgery to achieve 30% reduction in
IOP
 No treatment until evidence of
progression
 Other eye could be treated in this group
Collaborative Normal Tension Glaucoma (CNTGS)
Study design:
 In both arms, neither eye could receive beta-
adrenergic blockers or adrenergic agonists, because
they might have systemic cardiovascular effects that
could conceivably alter the course of the treated or
untreated disease, confounding the analysis of data.
7
2
CNTGS
RESULTS
 30% drop achieved in half without surgery
 Once 30% drop achieved rate of progressive field loss
was lower than group that did not receive treatment
(after allowing for cataract effect which was higher in
treated group)
CNTGS
RESULTS:
 Rate of progression in untreated NTG highly variable
 Half did not progress on VF in 5 years
 Factors associated with progression
 Female
 Migraine
 Disc haemorrhages on presentation
CNTG – results
 Prog in 12% of Rxed eyes & 35% in untreated group.
 30% reduction possible even by medicines.
 Treated pts that progressed
 Non IOP related
 target IOP wrong
CNGTS
 Overall, lowering IOP in NTG slows progression.
 However, over half of patients did not progress
without treatment at 5 years.
Collaborative Normal Tension Glaucoma (CNTGS)
IMPLICATIONS:
 The natural course of NTG is quite variable, some
cases slow enough that they may never need
treatment, but others progressing rapidly to
potential blindness.
7
7
 Because of the variable natural course of NTG, it is
important to distinguish between patients who have
progressive vs. non-progressive disease.
 In cases of mild NTG, consider monitoring until
progression is confirmed.
 However, factors that weigh more heavily for
treatment are female gender, history of migraine and
disc hemorrhage at diagnosis.
 When you suspect progression, be sure to confirm
that it is actual progression and not testing variability.
 This may require multiple visual fields to prevent
over-diagnosing progression.
 Once the decision is made to begin treatment, set a
goal (at least 30% IOP reduction) and be diligent in
attaining it.
 The large arsenal of IOP-lowering medications
available today makes this goal much more achievable
without surgery
TUBE V/S TRABECULECTOMY
(TVT)
TVT
 PURPOSE: To report 5 year treatment outcomes in
the tube versus trabeculectomy study.
 DESIGN: Multicenter randomized clinical trial
TVT
 STUDY POPULATION:
-Patients 18 to 85 years
-Prior cataract or glaucoma filtering surgery
- Uncontrolled glaucoma with IOP of 18mmHg to 40
mmHg on maximum tolerated medical therapy
 OUTCOME MEASURES
-IOP, Visual acuity, visual fields, surgical complications,
glaucoma medications and treatment failure
TVT
 RESULTS:
-Trabeculectomy with MMC and tube-shunt surgery
both produced sustained IOP reduction to the low
teens during 5 years of followup
-Tube-shunt surgery was associated with use of more
glaucoma medications than trabeculectomy with
MMC during the first 2 yrs of study,but medical
therapy equalized with longer followup
TVT
 RESULTS
-Trabeculectomy with MMC had a higher failure rate
(46.9%)compared with tube shunt surgery(29.8%)
-Higher rate of reoperation for glaucoma(29%)
compared to tube group(9%0
-vision loss occurred at similar rate in both groups
-Early postoperative complications occurred more
frequently after trabeculectomy with MMC relative to
tube shunt surgery.similar rate for late complications
TVT
 Implications
-No procedure superior for treating glaucoma
-Factors for selecting surgical procedure
o Surgeons skill and experience
o Patients willingness to undergo repeat glaucoma
surgery
o Surgeons planned surgical approach should failure
occur
 The researchers maintain that the TVT study does not
demonstrate clear superiority of one glaucoma
operation over the other, but that both surgeries are
viable options.
 Potential pitfalls exist with the use of tube shunts.
Subsequent surgical options after failure of tube-
shunt devices become limited—surgeons are left with
the choice of a second, inferiorly placed tube or
cyclophotocoagulation.
 The TVT Study supports the expanding use of tube
shunts beyond the surgical management of refractory
glaucoma.
 Tube shunt surgery was shown to be effective in a
patient population at lower risk of surgical failure
than has traditionally been designated for this
procedure.
 Trabeculectomy is not without its travails. It requires
the surgeon to tailor the procedure to each patient
(i.e., number of scleral flap sutures and dosage of an
antifibrotic agent) whereas tube-shunt surgery is a
more standardized procedure
 Also, trabeculectomies require more frequent and
more vigilant postoperative care than tube shunts.
OTHER IMPORTANT TRIALS
EUROPEAN GLAUCOMA PREVENTION
STUDY
 OBJECTIVE
Efficacy of reduction of IOP by dorzolamide versus
placebo in preventing or delaying POAG in patients
affected by Ocular hypertension
EGPS
 PARTICIPANTS:
-1081 patients
-Age ≥30 yrs
-IOP 22 to 29 mmHg
-2 normal and reliable visual fields
-Normal optic discs
 Outcome measures:
Safety end point was IOP >35 mmHg on 2 consecutive
examinations
EGPS
 RESULTS
-Dorzolamide reduced IOP by 15-22% in 5 yrs period
-At 60 months ,cumulative probability of converting to
an efficacy end point was
13.4%(dorzolamide group)
14.1%(placebo group)
-No statistically significant difference between medical
therapy and placebo group in reducing incidence of
POAG
EGPS
 Risk factors for progression
1.Older age
2.Thinner CCT
3.Higher vertical cup disc ratio
4.Higher Pattern standard deviation
EGPS
 The role of systemic blood pressure appears
important
 Regression to the Mean
 Minimised by multiple IOP measurements at different
times of the day (diurnal variation) or on a different
day.
 For each mm Hg higher IOP per 12 months, the risk
of converting to POAG in increased by 9% in the next
5 years.
LOW TENSION GLAUCOMA
PREVENTION STUDY
 OBJECTIVE
To evaluate visual field stability in low-pressure
glaucoma patients randomized to intraocular pressure
reduction in both eyes with topical twice daily
brimonidine tartrate 0.2% versus twice daily timolol
maleate 0.5%
LOGTS
 PARTICIPANTS
-Low-pressure glaucoma patients
- 30 years of age or older
-untreated pressure of more than 21 mmHg and
advanced visual field loss were excluded
 Randomization of both eyes to double-masked
monotherapy with brimonidine or timolol.
LOGTS
 Follow-up visits included Humphrey 24-2 full-
threshold perimetry, tonometry every 4 months, and
annual optic disc photography.
 MAIN OUTCOME MEASURE:
- Progression of visual field loss.
LOGTS
RESULTS
 showed similar IOP reduction for each medication.
 patients on brimonidine had less visual field loss
(9.1%) compared with patients on timolol (39.2%)
during an average of 30 months
 28 of the 99 patients in the brimonidine arm of the
study dropped out due to drug-related adverse events,
compared with only 9 of the 79 timolol patients
LOGTS
RESULTS
 low-pressure glaucoma patients treated with
brimonidine are less likely to have field progression
than patients treated with timolol
 Conclusion:
Brimonidine better than Timolol??
 The study attempted to find correlations between
many other baseline factors of the 2 study groups and
the slower progression of glaucoma in the group that
received brimonidine.
 Age, sex, family history, diabetes mellitus, risk factors
for low-tension glaucoma (such as migraine and the
Raynaud phenomenon), and ocular perfusion
pressure were investigated..
LOGTS
 Drawbacks
-Data may have been skewed due to the high number of
patients dropping out of the brimonidine group.
-No therapeutic goal for either medication
-Baseline untreated IOP was just over 15mm Hg and the
mean treated IOP was around 14mm Hg
LOGTS
 For now,we should use the therapy that reduces
IOP in normal-tension patients to significant
levels (minimum 30%), and modify treatment if
the optic nerve, retinal nerve fiber layer or visual
field changes.
 Prostaglandins have superb efficacy and less effect
than other agents in lowering heart rate. These
should be used as a first-line treatment whenever
possible.
 Remember to check blood pressure and heart rate before
initiating treatment with a beta-blocker such as timolol.
 Also, check if the patient is already taking a systemic beta-
blocker.
 Be sure that patients use timolol earlier in the evening
rather than before bedtime to avoid the hypotensive effect
that might compromise ocular blood flow and induce
systemic hypotension.
TAKE HOME MESSAGE
In OHT cases:
 Not all OHT need treatment – assess risk on
individual basis and then decide
 People with high risk factors may benefit from close
followup and early treatment
 Low risk patients can have less frequent followup and may
not need early treatment.
TAKE HOME MESSAGE
In NTG cases:
 Rate of progression in NTG highly variable
 Only proven treatment is reducing IOP
 Treat if risk factors present
TAKE HOME MESSAGE
POAG cases
 Start early treatment in diagnosed cases of POAG
 Choice of medical therapy first – change only if target
IOP not achieved.
 Surgical therapy safe
 In moderate to advanced disease initial surgical therapy
may be preferred
TAKE HOME MESSAGE
 Efficient patient care – practice of evidence based Rx
 IOP is the main risk factor for all glaucomas
 Recognize threat – lower IOP – lower risk of progression
 Set a target IOP after assessing risk factors for progression

More Related Content

What's hot

Transpupillary Thermotherapy (TTT)
Transpupillary Thermotherapy (TTT)Transpupillary Thermotherapy (TTT)
Transpupillary Thermotherapy (TTT)Pushkar Dhir
 
Surgical induced astigmatism
Surgical induced astigmatismSurgical induced astigmatism
Surgical induced astigmatismNamrata Gupta
 
Glaucoma optic disc changes
Glaucoma optic disc changesGlaucoma optic disc changes
Glaucoma optic disc changespragati jain
 
Cystoid macular oedema
Cystoid macular oedemaCystoid macular oedema
Cystoid macular oedemaArushi Prakash
 
Proliferative vitreoretinopathy
Proliferative vitreoretinopathyProliferative vitreoretinopathy
Proliferative vitreoretinopathyPavanShroff
 
Minimally invasive glaucoma surgery
Minimally invasive glaucoma surgery Minimally invasive glaucoma surgery
Minimally invasive glaucoma surgery aditisingh77985
 
Visual Field in Glaucoma
Visual Field in GlaucomaVisual Field in Glaucoma
Visual Field in Glaucomadocsarsi
 
Iol power calculation in pediatric patients
Iol power calculation in pediatric patientsIol power calculation in pediatric patients
Iol power calculation in pediatric patientsAnisha Rathod
 
Complications of trabeculectomy
Complications of trabeculectomyComplications of trabeculectomy
Complications of trabeculectomySumeet Agrawal
 
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY
OPTICAL COHERENCE TOMOGRAPHY  ANGIOGRAPHY  OPTICAL COHERENCE TOMOGRAPHY  ANGIOGRAPHY
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY Shruti Laddha
 
Optical coherence tomography in glaucoma - Dr Shylesh Dabke
Optical coherence tomography in glaucoma - Dr Shylesh DabkeOptical coherence tomography in glaucoma - Dr Shylesh Dabke
Optical coherence tomography in glaucoma - Dr Shylesh DabkeShylesh Dabke
 
Steroid Induced Glaucoma - Dr Shylesh B Dabke
Steroid Induced Glaucoma - Dr Shylesh B DabkeSteroid Induced Glaucoma - Dr Shylesh B Dabke
Steroid Induced Glaucoma - Dr Shylesh B DabkeShylesh Dabke
 

What's hot (20)

Normal tension glaucoma
Normal tension glaucomaNormal tension glaucoma
Normal tension glaucoma
 
Transpupillary Thermotherapy (TTT)
Transpupillary Thermotherapy (TTT)Transpupillary Thermotherapy (TTT)
Transpupillary Thermotherapy (TTT)
 
Oct in glaucoma
Oct in glaucomaOct in glaucoma
Oct in glaucoma
 
Surgical induced astigmatism
Surgical induced astigmatismSurgical induced astigmatism
Surgical induced astigmatism
 
Target IOP Lt Col Rashed
Target IOP Lt Col RashedTarget IOP Lt Col Rashed
Target IOP Lt Col Rashed
 
Glaucoma optic disc changes
Glaucoma optic disc changesGlaucoma optic disc changes
Glaucoma optic disc changes
 
Cystoid macular oedema
Cystoid macular oedemaCystoid macular oedema
Cystoid macular oedema
 
Congenital ptosis
Congenital ptosisCongenital ptosis
Congenital ptosis
 
Proliferative vitreoretinopathy
Proliferative vitreoretinopathyProliferative vitreoretinopathy
Proliferative vitreoretinopathy
 
Minimally invasive glaucoma surgery
Minimally invasive glaucoma surgery Minimally invasive glaucoma surgery
Minimally invasive glaucoma surgery
 
Visual Field in Glaucoma
Visual Field in GlaucomaVisual Field in Glaucoma
Visual Field in Glaucoma
 
Iol power calculation in pediatric patients
Iol power calculation in pediatric patientsIol power calculation in pediatric patients
Iol power calculation in pediatric patients
 
Cystoid macular oedema
Cystoid macular oedemaCystoid macular oedema
Cystoid macular oedema
 
Ocular hypertension
Ocular hypertensionOcular hypertension
Ocular hypertension
 
Complications of trabeculectomy
Complications of trabeculectomyComplications of trabeculectomy
Complications of trabeculectomy
 
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY
OPTICAL COHERENCE TOMOGRAPHY  ANGIOGRAPHY  OPTICAL COHERENCE TOMOGRAPHY  ANGIOGRAPHY
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY
 
Optical coherence tomography in glaucoma - Dr Shylesh Dabke
Optical coherence tomography in glaucoma - Dr Shylesh DabkeOptical coherence tomography in glaucoma - Dr Shylesh Dabke
Optical coherence tomography in glaucoma - Dr Shylesh Dabke
 
Macular hole
Macular holeMacular hole
Macular hole
 
Steroid Induced Glaucoma - Dr Shylesh B Dabke
Steroid Induced Glaucoma - Dr Shylesh B DabkeSteroid Induced Glaucoma - Dr Shylesh B Dabke
Steroid Induced Glaucoma - Dr Shylesh B Dabke
 
Corneal drawings
Corneal drawingsCorneal drawings
Corneal drawings
 

Viewers also liked

Viewers also liked (6)

Corneal dystrophy
Corneal dystrophy Corneal dystrophy
Corneal dystrophy
 
Embryology applied anatomy and physiology of lens
Embryology applied anatomy and physiology of lensEmbryology applied anatomy and physiology of lens
Embryology applied anatomy and physiology of lens
 
Eye Embryology- basic (my notes)
Eye Embryology- basic (my notes)Eye Embryology- basic (my notes)
Eye Embryology- basic (my notes)
 
Ocular pharmacology
Ocular pharmacologyOcular pharmacology
Ocular pharmacology
 
Congenital glaucoma
Congenital glaucomaCongenital glaucoma
Congenital glaucoma
 
Embryology of eye
Embryology of eyeEmbryology of eye
Embryology of eye
 

Similar to Important trials in Glaucoma

Management of early glaucoma: Evidence based medicine
Management of early glaucoma: Evidence based medicineManagement of early glaucoma: Evidence based medicine
Management of early glaucoma: Evidence based medicineHind Safwat
 
The Glymphatic System and New Etiopathogenic Hypotheses Concerning Glaucoma B...
The Glymphatic System and New Etiopathogenic Hypotheses Concerning Glaucoma B...The Glymphatic System and New Etiopathogenic Hypotheses Concerning Glaucoma B...
The Glymphatic System and New Etiopathogenic Hypotheses Concerning Glaucoma B...IJCROOJournal
 
Ocular Hypertension Treatment study (OHTS).pptx
Ocular Hypertension Treatment  study (OHTS).pptxOcular Hypertension Treatment  study (OHTS).pptx
Ocular Hypertension Treatment study (OHTS).pptxRashtriyaSamajseviPa
 
Iop compliance and fluctuations
Iop compliance and fluctuationsIop compliance and fluctuations
Iop compliance and fluctuationsMichael Duplessie
 
Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...
Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...
Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...CrimsonpublishersMSOR
 
Medical management of glaucoma
Medical management of glaucomaMedical management of glaucoma
Medical management of glaucomaKumarSingh44
 
Angle Recession Glaucoma
Angle Recession GlaucomaAngle Recession Glaucoma
Angle Recession GlaucomaFahmida Hoque
 
Patient Compliance To Treatment In The Management Of Glaucoma And Factors Aff...
Patient Compliance To Treatment In The Management Of Glaucoma And Factors Aff...Patient Compliance To Treatment In The Management Of Glaucoma And Factors Aff...
Patient Compliance To Treatment In The Management Of Glaucoma And Factors Aff...Dr. Jagannath Boramani
 
Glaucoma Filtration Surgery Study
Glaucoma Filtration Surgery StudyGlaucoma Filtration Surgery Study
Glaucoma Filtration Surgery StudyFarhadul Alam
 
Treatment of Diabetic Macular Edema with Aflibercept and Micropulse Laser (DA...
Treatment of Diabetic Macular Edema with Aflibercept and Micropulse Laser (DA...Treatment of Diabetic Macular Edema with Aflibercept and Micropulse Laser (DA...
Treatment of Diabetic Macular Edema with Aflibercept and Micropulse Laser (DA...haha haha
 
Effetti a lungo termine dell'associazione a dose fissa di latanoprost e timol...
Effetti a lungo termine dell'associazione a dose fissa di latanoprost e timol...Effetti a lungo termine dell'associazione a dose fissa di latanoprost e timol...
Effetti a lungo termine dell'associazione a dose fissa di latanoprost e timol...Merqurio
 
Diabetic retinopathy guidlines
Diabetic retinopathy guidlinesDiabetic retinopathy guidlines
Diabetic retinopathy guidlinesmfh5818
 
Comparison of latanoprost, bimatoprost and travoprost
Comparison of latanoprost, bimatoprost and travoprostComparison of latanoprost, bimatoprost and travoprost
Comparison of latanoprost, bimatoprost and travoprostAvaleks-Kiev
 
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...QUESTJOURNAL
 

Similar to Important trials in Glaucoma (20)

Management of early glaucoma: Evidence based medicine
Management of early glaucoma: Evidence based medicineManagement of early glaucoma: Evidence based medicine
Management of early glaucoma: Evidence based medicine
 
The Glymphatic System and New Etiopathogenic Hypotheses Concerning Glaucoma B...
The Glymphatic System and New Etiopathogenic Hypotheses Concerning Glaucoma B...The Glymphatic System and New Etiopathogenic Hypotheses Concerning Glaucoma B...
The Glymphatic System and New Etiopathogenic Hypotheses Concerning Glaucoma B...
 
Ocular Hypertension Treatment study (OHTS).pptx
Ocular Hypertension Treatment  study (OHTS).pptxOcular Hypertension Treatment  study (OHTS).pptx
Ocular Hypertension Treatment study (OHTS).pptx
 
Iop compliance and fluctuations
Iop compliance and fluctuationsIop compliance and fluctuations
Iop compliance and fluctuations
 
Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...
Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...
Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...
 
Ocular Hypertension
Ocular HypertensionOcular Hypertension
Ocular Hypertension
 
Medical management of glaucoma
Medical management of glaucomaMedical management of glaucoma
Medical management of glaucoma
 
Target IOP
Target IOPTarget IOP
Target IOP
 
Angle Recession Glaucoma
Angle Recession GlaucomaAngle Recession Glaucoma
Angle Recession Glaucoma
 
Patient Compliance To Treatment In The Management Of Glaucoma And Factors Aff...
Patient Compliance To Treatment In The Management Of Glaucoma And Factors Aff...Patient Compliance To Treatment In The Management Of Glaucoma And Factors Aff...
Patient Compliance To Treatment In The Management Of Glaucoma And Factors Aff...
 
Glaucoma Filtration Surgery Study
Glaucoma Filtration Surgery StudyGlaucoma Filtration Surgery Study
Glaucoma Filtration Surgery Study
 
Treatment of Diabetic Macular Edema with Aflibercept and Micropulse Laser (DA...
Treatment of Diabetic Macular Edema with Aflibercept and Micropulse Laser (DA...Treatment of Diabetic Macular Edema with Aflibercept and Micropulse Laser (DA...
Treatment of Diabetic Macular Edema with Aflibercept and Micropulse Laser (DA...
 
International Journal of Ophthalmology & Vision Research
International Journal of Ophthalmology & Vision ResearchInternational Journal of Ophthalmology & Vision Research
International Journal of Ophthalmology & Vision Research
 
International Journal of Ophthalmology & Vision Research
International Journal of Ophthalmology & Vision ResearchInternational Journal of Ophthalmology & Vision Research
International Journal of Ophthalmology & Vision Research
 
G19ur.pptx
G19ur.pptxG19ur.pptx
G19ur.pptx
 
Effetti a lungo termine dell'associazione a dose fissa di latanoprost e timol...
Effetti a lungo termine dell'associazione a dose fissa di latanoprost e timol...Effetti a lungo termine dell'associazione a dose fissa di latanoprost e timol...
Effetti a lungo termine dell'associazione a dose fissa di latanoprost e timol...
 
Diabetic retinopathy guidlines
Diabetic retinopathy guidlinesDiabetic retinopathy guidlines
Diabetic retinopathy guidlines
 
Comparison of latanoprost, bimatoprost and travoprost
Comparison of latanoprost, bimatoprost and travoprostComparison of latanoprost, bimatoprost and travoprost
Comparison of latanoprost, bimatoprost and travoprost
 
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...
 
Pituitary disease
Pituitary diseasePituitary disease
Pituitary disease
 

More from Laxmi Eye Institute (20)

Supranuclear pathways and lesions
Supranuclear pathways and lesionsSupranuclear pathways and lesions
Supranuclear pathways and lesions
 
IOL power calculation special situations
IOL power calculation special situations IOL power calculation special situations
IOL power calculation special situations
 
Ice syndrome
Ice syndromeIce syndrome
Ice syndrome
 
Scleritis a case presentation
Scleritis a case presentationScleritis a case presentation
Scleritis a case presentation
 
Visual pathway
Visual pathway Visual pathway
Visual pathway
 
CCP
CCPCCP
CCP
 
Ocular tb
Ocular tbOcular tb
Ocular tb
 
Causes of low vision in adult
Causes of low vision in adultCauses of low vision in adult
Causes of low vision in adult
 
Trial set
Trial setTrial set
Trial set
 
ASSESMENT OF VISUAL ACUITY IN CHILDREN
ASSESMENT OF VISUAL ACUITY IN CHILDRENASSESMENT OF VISUAL ACUITY IN CHILDREN
ASSESMENT OF VISUAL ACUITY IN CHILDREN
 
INTRAOCULAR FOREIGN BODY
INTRAOCULAR FOREIGN BODYINTRAOCULAR FOREIGN BODY
INTRAOCULAR FOREIGN BODY
 
VITAMIN A & VISUAL CYCLE
VITAMIN A & VISUAL CYCLEVITAMIN A & VISUAL CYCLE
VITAMIN A & VISUAL CYCLE
 
Malignant glaucoma
Malignant glaucomaMalignant glaucoma
Malignant glaucoma
 
Lasers in Glaucoma
Lasers in GlaucomaLasers in Glaucoma
Lasers in Glaucoma
 
Uveitic Glaucoma
Uveitic GlaucomaUveitic Glaucoma
Uveitic Glaucoma
 
Central Retinal Vein OcclUsIon (CRUISE) Study - Cruise trial
Central Retinal  Vein OcclUsIon (CRUISE) Study - Cruise trialCentral Retinal  Vein OcclUsIon (CRUISE) Study - Cruise trial
Central Retinal Vein OcclUsIon (CRUISE) Study - Cruise trial
 
Colour vision and its clinical aspects
Colour vision and its clinical aspectsColour vision and its clinical aspects
Colour vision and its clinical aspects
 
Automated perimetry
Automated perimetryAutomated perimetry
Automated perimetry
 
Ectopia lentis
Ectopia lentisEctopia lentis
Ectopia lentis
 
Accommodative esotropia
Accommodative esotropiaAccommodative esotropia
Accommodative esotropia
 

Recently uploaded

Health literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptxHealth literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptxPamela McKinney
 
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete HealthLiving Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete HealthLyons Health
 
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsArtificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsIris Thiele Isip-Tan
 
Empathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion insteadEmpathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion insteadAlex Clapson
 
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHYCECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHYRMC
 
ACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousKR_Barker
 
Eating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports PsychologyEating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports Psychologyshantisphysio
 
21 NEMT Trends & Statistics to Know in 2024
21 NEMT Trends & Statistics to Know in 202421 NEMT Trends & Statistics to Know in 2024
21 NEMT Trends & Statistics to Know in 2024Traumasoft LLC
 
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
LARYNGEAL CANCER.pptx  Prepared by Neha KewatLARYNGEAL CANCER.pptx  Prepared by Neha Kewat
LARYNGEAL CANCER.pptx Prepared by Neha KewatNehaKewat
 
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdfCompliatric Where Compliance Happens
 
Hematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of HematinicsHematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of Hematinicsnetraangadi2
 
EYE CANCER.pptx prepared by Neha kewat digital learning
EYE CANCER.pptx prepared by  Neha kewat digital learningEYE CANCER.pptx prepared by  Neha kewat digital learning
EYE CANCER.pptx prepared by Neha kewat digital learningNehaKewat
 
Assisted Living Care Residency - PapayaCare
Assisted Living Care Residency - PapayaCareAssisted Living Care Residency - PapayaCare
Assisted Living Care Residency - PapayaCareratilalthakkar704
 
Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)bishwabandhuniraula
 
Pharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxPharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxCliniminds India
 
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdfDolisha Warbi
 

Recently uploaded (20)

Health literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptxHealth literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptx
 
SCOPE OF CRITICAL CARE ORGANIZATION
SCOPE OF CRITICAL CARE ORGANIZATIONSCOPE OF CRITICAL CARE ORGANIZATION
SCOPE OF CRITICAL CARE ORGANIZATION
 
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete HealthLiving Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
 
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsArtificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
 
Empathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion insteadEmpathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion instead
 
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHYCECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
 
The Power of Active listening - Tool in effective communication.pdf
The Power of Active listening - Tool in effective communication.pdfThe Power of Active listening - Tool in effective communication.pdf
The Power of Active listening - Tool in effective communication.pdf
 
ACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the Curious
 
Eating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports PsychologyEating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports Psychology
 
21 NEMT Trends & Statistics to Know in 2024
21 NEMT Trends & Statistics to Know in 202421 NEMT Trends & Statistics to Know in 2024
21 NEMT Trends & Statistics to Know in 2024
 
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
LARYNGEAL CANCER.pptx  Prepared by Neha KewatLARYNGEAL CANCER.pptx  Prepared by Neha Kewat
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
 
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
 
Annual Training
Annual TrainingAnnual Training
Annual Training
 
Painting Rats White Angers Them to No End
Painting Rats White Angers Them to No EndPainting Rats White Angers Them to No End
Painting Rats White Angers Them to No End
 
Hematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of HematinicsHematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of Hematinics
 
EYE CANCER.pptx prepared by Neha kewat digital learning
EYE CANCER.pptx prepared by  Neha kewat digital learningEYE CANCER.pptx prepared by  Neha kewat digital learning
EYE CANCER.pptx prepared by Neha kewat digital learning
 
Assisted Living Care Residency - PapayaCare
Assisted Living Care Residency - PapayaCareAssisted Living Care Residency - PapayaCare
Assisted Living Care Residency - PapayaCare
 
Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)
 
Pharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxPharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptx
 
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
 

Important trials in Glaucoma

  • 1. IMPORTANT TRIALS IN GLAUCOMA Presenter-Dr Ravneet Moderator- Dr Hetal Shah Dr Rita Dhamankar Dr Vijay Shetty
  • 2. Landmark studies in glaucoma  Ocular Hypertension Treatment study (OHTS)  Collaborative Initial Glaucoma treatment Study (CIGTS)  Advanced Glaucoma Intervention Study (AGIS)  Early Manifest Glaucoma trial (EMGT)  Collaborative Normal Tension Glaucoma (CNTGS)  Tube versus Trabeculectomy study (TVT)  European Glaucoma prevention study(EGPS)  Low Tension Glaucoma prevention Study(LoGTS)
  • 3. Ocular Hypertension Treatment study (OHTS) 3 Arch Ophthalmol 120: 701-713, 2002.
  • 4. Ocular Hypertension Treatment study (OHTS) Objective:  To evaluate the safety and efficacy of topical ocular hypotensive medications in preventing or delaying onset of visual field loss and or optic nerve damage in subjects with ocular hypertension.  Identify baseline demographic and clinical factors that predict which participants will develop POAG 4
  • 5. Ocular Hypertension Treatment study (OHTS) Participants:  1637 patients with ocular hypertension recruited between 1994 and 1996 Study design:  Multicentre randomized controlled clinical trial comparing observation with medical therapy for ocular hypertension. 5
  • 6. Methods:  1637 participants  no evidence of glaucomatous damage,  40 to 80 years  IOP 24 mmHg - 32 mmHg in one eye 21mmHg and 32 mmHg in other eye  The goal in the medication group was to reduce the IOP by 20% or more and to reach an IOP of 24 mmHg or less. Ocular Hypertension Treatment study (OHTS)
  • 7. OHTS Phase 1 Begins February 28, 1994 Eligibility Criteria Medication Topical treatment to lower IOP 20% and IOP < 24 mm Hg Observation No topical treatment to lower IOP Randomization Reproducible Abnormality 3 consecutive visual fields and/or 2 consecutive sets of optic disc photographs Monitoring Humphrey 30-2 q6 months Stereoscopic disc photos annually POAG Visual field and/or optic disc changes attributed to POAG Adjust therapy if target not met
  • 8. Ocular Hypertension Treatment study (OHTS) Results : At 5 years followup  Incidence of POAG 9.5% in controls 4.4% in treatment group  22.5% decrease in IOP in the treatment group 8
  • 9. OHTS Summary of results CCT < 555 & IOP > 25 CCT < 555 & CD > 0.5 Risk 36% Risk 22% CCT > 588 &IOP > 25 CCT > 588 & CD >0.5 Risk 6% Risk 8%
  • 10. Ocular Hypertension Treatment study (OHTS) Increased risk of the onset of POAG was associated with:  Increased age  Vertical and horizontal cup disc ratio  Pattern standard deviation  IOP at baseline  Central corneal thickness (CCT) was found to be a powerful predictor for the development of POAG.
  • 11. Ocular Hypertension Treatment study (OHTS)  The corneas in OHTS subjects were thicker  lower corneal thickness in black subjects than whites.  The effect of CCT may influence the accuracy of applanation tonometry in the diagnosis, screening and management of patients with glaucoma and ocular hypertension. 1 2
  • 12. Clinical useful points from OHTS  OHT – What to do * Treat all * Treat no one * Treat some -- Is treatment effective DOES OHTS HAVE ANSWERS FOR THIS
  • 13. Clinical useful points from OHTS  Treat only patients at high risk.  Risk factors – risk calculator www.discoveriesinsight.org  Importance of CCT  ONH & VF monitoring at every FU  Study – Rx effective , of the 9.6% that converted half could be prevented by Rx  OHTS - ? Conversion after longer FU Age Vertical C/D IOP DM+ CCT PSD If not high risk waiting to treat OHT till conversion- better strategy ( vision related QOL)
  • 14. OHTS PHASE2 March OHTS Phase 2 Medication Group N = 694 Medication is continued in the Medication group OHTS Phase 2 N = 672 Medication is Initiated in the Observation group
  • 15. OHTS Phase 2: Rationale  OHTS Phase 1 provides proof of concept: medication reduces the incidence of POAG.  OHTS Phase 1 does not indicate when medication should begin.  OHTS Phase 1 does not indicate if all OHT patients should receive early medication.
  • 16. OHTS Phase 2: Methods After 7.5 years of observation, participants originally randomized to observation group start medication. This creates: Delayed treatment group Observation group followed for 7.5 years then treated for 5.5 years Early treatment group Medication group treated for median of 13 years from the beginning Compare incidence of POAG at 13.0 years
  • 17. OHTS PHASE 2 RESULTS  Median Time to develop POAG: Observation group-6 yrs Medication group-8.7 yrs  Increased cumulative incidence of POAG at 13 yrs (22% vs 16%)  More eyes with structural and functional damage(8% vs 5%)  More participants with bilateral disease (6% vs 4%)
  • 18. Ocular Hypertension Treatment study (OHTS)  The primary purpose of the follow up study was to determine whether delaying treatment resulted in persistently increased risk of conversion to glaucoma, even after the initiation of therapy. 2 0
  • 19. Ocular Hypertension Treatment study (OHTS) Implications:  Ocular hypertensives can be seperated into categories of high,medium & low risk.  People with high risk factors may benefit from close followup and early treatment  Low risk patients can have less frequent followup and may not need early treatment. 2 1
  • 20. Ocular Hypertension Treatment study (OHTS  Subjects with corneal thickness of 555μm or less had three times the risk of developing primary open-angle glaucoma compared with those who had corneal thickness of 588μm or more.  Therefore, measure central corneal thickness of all new glaucoma suspects.
  • 21. Early Manifest Glaucoma trial (EMGT) 2 4
  • 22. Early Manifest Glaucoma trial (EMGT) Purpose:  To compare the effect of immediate therapy to lower the intraocular pressure versus late or no treatment on the progression of newly detected open-angle glaucoma,as measured by increasing visual field loss and or optic disc changes 2 5
  • 23. Early Manifest Glaucoma trial (EMGT) Participants:  Newly diagnosed POAG patients (255)  50 to 80 years of age  255 patients were randomized between 1993 and 1997. 2 6
  • 24. Early Manifest Glaucoma trial (EMGT) Study design:  Multicenter randomized controlled clinical trial comparing observation with betaxolol and argon laser trabeculoplasty for OAG. 2 7
  • 25. EMGT • Randomised to -ALT and betaxolol -No treatment • If IOP >25mmHg in treated (>35 untreated) → Latanoprost added • If remains high → individualised treatment
  • 26. Early Manifest Glaucoma trial (EMGT) Results:  At 6 years, 62% of untreated patients showed progression, whereas 45% of treated patients progressed. Treatment reduced IOP by 25%.  Median time to progression 66 months in treated versus 48 months in untreated . 2 9
  • 27. EMGTS – results  Progression  62% - control  45% - treated group  25% IOP - risk of progression by 50%  Risk of progression less with larger initial IOP drop  Risk of progression by 10% / mm Hg IOP from baseline
  • 28. Early Manifest Glaucoma trial (EMGT)  In the control group , the rate of visual field progression was fastest in the subgroup of patients with exfoliation and slowest in those with normal IOPs at baseline. 3 1
  • 29. Early Manifest Glaucoma trial (EMGT) Baseline risk factors:  Higher IOP  Exfoliation  Older age  Lower systolic perfusion pressure  Lower CCT among patients with higher IOPs  follow up higher IOP,  disc hemorrhages. 3 2
  • 30. Early Manifest Glaucoma trial (EMGT) Implications:  In eyes with glaucoma ,IOP that was lowered by an average of 25%, treatment was of benefit versus no treatment .  There is beneficial effect of immediate therapy to lower the intraocular pressure versus late or no treatment on the progression of newly detected OAG 3 3
  • 31. Clinical Implications  Even small reductions in IOP can make a difference.  Every 1mm of IOP reduction was associated with a risk reduction of 10% to 13%, depending on the analysis,  But that doesn't necessarily mean all patients must be treated, because we can't know which patients will progress, in some cases, we can observe closely and tailor management to the individual patient  It's beneficial to lower pressure in patients progressing quickly, even if IOP levels have been in the range of 15 to 18mm Hg,
  • 32. Clinical useful points from EMGTS  25% IOP - progression from 62 – 45%  Regular FU every 3 – 6 months with ONH & VF must – not commonly practiced.  Pts with low risk of progression left untreated – no effect on QOL till lifetime  Drawbacks – Rx options limited – better drugs now
  • 33. Collaborative Initial Glaucoma treatment Study (CIGTS) Am J Ophthalmol 1998;126:498-505
  • 34. Collaborative Initial Glaucoma treatment Study (CIGTS) Purpose:  To determine whether patients with newly diagnosed open angle glaucoma (OAG) are better treated by initial treatment with medications or by immediate filtering surgery.  In addition, a secondary measure—a health- related quality of life questionnaire—looked at how the treatment affected the patient's lifestyle.3 9
  • 35. Collaborative Initial Glaucoma treatment Study (CIGTS) Participants:  607 patients with OAG ( primary, pigmentary, or pseudoexfoliative) recruited between 1993 and 1997. Study design:  Multicenter randomized controlled clinical trial comparing initial medical with initial surgical therapy for OAG. 4 0
  • 36.  First time the concept of Target IOP was used. March CIGTS MEDICATION GROUP N = 307 SURGICAL GROUP N = 300
  • 37. CIGTS  RESULTS  At 5 yrs both effective  Control of IOP lower by surgery (48%), medical (35%)  VF loss greater in surgery (cataract)  QOL initially better with medical group
  • 38. CIGTS – Results at 5yrs Medical Treatment Surgical Treatment IOP reduction 28mmHg→17-18mmHg (38%) 27mmHg→14-15mmHg (46%) Progression at 5 years No progression No progression • Surgical group is at increased risk of visual loss initially but by 4yrs both groups are comparable •The rate of cataract removal was greater in the surgically treated group.
  • 39. Collaborative Initial Glaucoma treatment Study (CIGTS) Results  Patients with diabetes were more likely to progress if treated with surgery first.  The quality of life (QOL) impact reported by the 2 treatment groups was very similar.  Increased impact of local eye symptoms reported by the surgery group 4 5
  • 40. Collaborative Initial Glaucoma treatment Study (CIGTS) Results  The overall rate of progression of OAG in CIGTS was lower than in many clinical trials, potentially the result of more aggressive IOP goals and the stage of the disease.
  • 41. CIGTS summary  Surgery resulted in  Lower IOP  More cataract  More ocular side effects  Initial ↓ vision  Initial ↓ visual field
  • 42. Collaborative Initial Glaucoma treatment Study (CIGTS) Implications  In moderate to advanced disease initial surgical therapy may be preferred.  The results also revealed that either treatment had a remarkably similar effect on patients' quality of life.  Though not associated with a particular treatment group, the fear of blindness was common, affecting 34% at diagnosis.  Patients who reported a decrease in visual functioning were more likely to experience depression and mood changes 4 8
  • 43. Clinical useful points from CIGTS  Early POAG – medical Rx effective  Our scenario – compliance/cost – deciding factor for either modality  Concept of target IOP – must in our management.  Drawback – study duration too short for Rx recommendation.
  • 45. Advanced Glaucoma Intervention Study (AGIS) Purpose: To compare the clinical outcomes of 2 treatment sequences in cases of advanced glaucoma 5 2
  • 46. Advanced glaucoma intervention study (AGIS)  Objective – to determine if ALT or surgery is preferred Rx for advanced glaucoma on max tolerated medical Rx. 789 eyes ALT TRAB TRAB (ATT) TRAB ALT TRAB (TAT)
  • 47. Advanced Glaucoma Intervention Study (AGIS) Participants:  789 eyes of 591 patients with medically uncontrolled OAG recruited from 1988 to 1992.  POAG uncontrolled on maximum accepted and tolerated medical therapy(IOP ≥ 18 mm Hg)  35 to 80 yr 5 4
  • 48. Advanced Glaucoma Intervention Study (AGIS) Study design:  Multicenter randomized controlled clinical trial comparing 2 treatment sequences (TAT and ATT ) for patients with OAG uncontrolled by medical therapy.
  • 49. Advanced Glaucoma Intervention Study (AGIS) Results:  Black patients had less combined visual acuity and visual field loss if treated with the ATT sequence.  White patients had less combined visual acuity and visual field loss at 7 years if treated with the TAT sequence.  Visual function scores improved after cataract surgery. 5 6
  • 50. AGIS - Results  Relationship of IOP & VF progression.  Predictive analysis – IOP < 14 mm Hg did better  Associative analysis – low IOP & low IOP fluctuation - Decreased progression
  • 51. Advanced Glaucoma Intervention Study (AGIS Results:  Lower IOP was associated with less visual field loss.  First 18 months after the first surgical intervention, or eyes with IOP of 18mmHg or less at all visits throughout the study had significantly less visual field loss  Approximately half of the study patients developed cataract in the first 5 years of follow up.  Trabeculectomy increases the relative risk of cataract formation by 78%. 5 8
  • 52. Advanced Glaucoma Intervention Study (AGIS) Results  ALT failure is associated with -younger age -higher IOP.  Trabeculectomy failure associated with -younger age, -higher IOP, -diabetes, and postoperative complications such as particularly elevated IOP and marked inflammation. -IOP fluctuation was an independent predictor of progression of OAG in eye with lower baseline IOPs.
  • 53. Results - AGIS  TAT  IOP  Better for whites  ATT  Failure  Better for blacks Risk of cataract after TRAB after 5 years – 78 %
  • 54. AGIS  Effects of IOP on visual field progression were also specifically evaluated from AGIS data, and it was found that patients with an average IOP of greater than 17.5mm Hg had greater worsening of their visual fields than those with an average IOP of less than 14mm Hg.  AGIS was one of the first studies to show that lower mean IOP results in a decreased risk of visual field progression.
  • 55. AGIS  Each patient requires individualized care.  AGIS demonstrated that race is an important consideration for surgical intervention in advanced glaucoma.  This is not to say, for instance, that a white patient with medically-uncontrolled glaucoma should only be offered the option of trabeculectomy.  Potential operative complications associated with the more invasive surgery may sway the patient toward laser intervention as a first option.
  • 56. AGIS  Conversely, a black patient presented with the option of laser intervention should be warned of the likely future need for both additional medications and additional glaucoma surgery after the laser procedure is completed.
  • 57. AGIS  There is no magic number for target IOP.  Patients in the AGIS group who consistently maintained IOP less than 18mm Hg at every visit over six years, with mean IOP of 12.3mm Hg as a group, had good preservation of visual field—yet a number of patients in this group still showed progressive visual field loss.
  • 58. Advanced Glaucoma Intervention Study (AGIS) Implications:  Keep race in mind when choosing therapy.  Lower IOP was associated with less visual field loss  IOP fluctuation was an independent predictor of progression of OAG in eye with lower baseline IOPs. 6 5
  • 60.  Lowering IOP in patients with normal-tension glaucoma (NTG) can be challenging.  Is it even worth trying to lower an already-low IOP?
  • 61. Collaborative Normal Tension Glaucoma (CNTGS) Purpose:  To determine if IOP plays a part in the pathogenic process of NTG by comparing a treatment group (with a 30% reduction in IOP) to a no treatment group. . 6 8
  • 62. Collaborative Normal Tension Glaucoma (CNTGS) Participants :  230 patients  20-90 yrs  Patients had unilateral or bilateral NTG  Three reliable visual fields within 1 month  Average IOP ≤20 mmHg,no reading above 24 mmHg 6 9
  • 63. NTGS - methods  Randomised immediately if  VF defect threatening fixation  Previously documented disease progression  Others randomised when evidence of progression
  • 64. NTGS  145 (of 239) patients randomised  One eye randomised to  Treatment  Drops, ALT or surgery to achieve 30% reduction in IOP  No treatment until evidence of progression  Other eye could be treated in this group
  • 65. Collaborative Normal Tension Glaucoma (CNTGS) Study design:  In both arms, neither eye could receive beta- adrenergic blockers or adrenergic agonists, because they might have systemic cardiovascular effects that could conceivably alter the course of the treated or untreated disease, confounding the analysis of data. 7 2
  • 66. CNTGS RESULTS  30% drop achieved in half without surgery  Once 30% drop achieved rate of progressive field loss was lower than group that did not receive treatment (after allowing for cataract effect which was higher in treated group)
  • 67. CNTGS RESULTS:  Rate of progression in untreated NTG highly variable  Half did not progress on VF in 5 years  Factors associated with progression  Female  Migraine  Disc haemorrhages on presentation
  • 68. CNTG – results  Prog in 12% of Rxed eyes & 35% in untreated group.  30% reduction possible even by medicines.  Treated pts that progressed  Non IOP related  target IOP wrong
  • 69. CNGTS  Overall, lowering IOP in NTG slows progression.  However, over half of patients did not progress without treatment at 5 years.
  • 70. Collaborative Normal Tension Glaucoma (CNTGS) IMPLICATIONS:  The natural course of NTG is quite variable, some cases slow enough that they may never need treatment, but others progressing rapidly to potential blindness. 7 7
  • 71.  Because of the variable natural course of NTG, it is important to distinguish between patients who have progressive vs. non-progressive disease.  In cases of mild NTG, consider monitoring until progression is confirmed.  However, factors that weigh more heavily for treatment are female gender, history of migraine and disc hemorrhage at diagnosis.
  • 72.  When you suspect progression, be sure to confirm that it is actual progression and not testing variability.  This may require multiple visual fields to prevent over-diagnosing progression.  Once the decision is made to begin treatment, set a goal (at least 30% IOP reduction) and be diligent in attaining it.  The large arsenal of IOP-lowering medications available today makes this goal much more achievable without surgery
  • 74. TVT  PURPOSE: To report 5 year treatment outcomes in the tube versus trabeculectomy study.  DESIGN: Multicenter randomized clinical trial
  • 75. TVT  STUDY POPULATION: -Patients 18 to 85 years -Prior cataract or glaucoma filtering surgery - Uncontrolled glaucoma with IOP of 18mmHg to 40 mmHg on maximum tolerated medical therapy  OUTCOME MEASURES -IOP, Visual acuity, visual fields, surgical complications, glaucoma medications and treatment failure
  • 76. TVT  RESULTS: -Trabeculectomy with MMC and tube-shunt surgery both produced sustained IOP reduction to the low teens during 5 years of followup -Tube-shunt surgery was associated with use of more glaucoma medications than trabeculectomy with MMC during the first 2 yrs of study,but medical therapy equalized with longer followup
  • 77. TVT  RESULTS -Trabeculectomy with MMC had a higher failure rate (46.9%)compared with tube shunt surgery(29.8%) -Higher rate of reoperation for glaucoma(29%) compared to tube group(9%0 -vision loss occurred at similar rate in both groups -Early postoperative complications occurred more frequently after trabeculectomy with MMC relative to tube shunt surgery.similar rate for late complications
  • 78. TVT  Implications -No procedure superior for treating glaucoma -Factors for selecting surgical procedure o Surgeons skill and experience o Patients willingness to undergo repeat glaucoma surgery o Surgeons planned surgical approach should failure occur
  • 79.  The researchers maintain that the TVT study does not demonstrate clear superiority of one glaucoma operation over the other, but that both surgeries are viable options.  Potential pitfalls exist with the use of tube shunts. Subsequent surgical options after failure of tube- shunt devices become limited—surgeons are left with the choice of a second, inferiorly placed tube or cyclophotocoagulation.
  • 80.  The TVT Study supports the expanding use of tube shunts beyond the surgical management of refractory glaucoma.  Tube shunt surgery was shown to be effective in a patient population at lower risk of surgical failure than has traditionally been designated for this procedure.
  • 81.  Trabeculectomy is not without its travails. It requires the surgeon to tailor the procedure to each patient (i.e., number of scleral flap sutures and dosage of an antifibrotic agent) whereas tube-shunt surgery is a more standardized procedure  Also, trabeculectomies require more frequent and more vigilant postoperative care than tube shunts.
  • 83. EUROPEAN GLAUCOMA PREVENTION STUDY  OBJECTIVE Efficacy of reduction of IOP by dorzolamide versus placebo in preventing or delaying POAG in patients affected by Ocular hypertension
  • 84. EGPS  PARTICIPANTS: -1081 patients -Age ≥30 yrs -IOP 22 to 29 mmHg -2 normal and reliable visual fields -Normal optic discs  Outcome measures: Safety end point was IOP >35 mmHg on 2 consecutive examinations
  • 85. EGPS  RESULTS -Dorzolamide reduced IOP by 15-22% in 5 yrs period -At 60 months ,cumulative probability of converting to an efficacy end point was 13.4%(dorzolamide group) 14.1%(placebo group) -No statistically significant difference between medical therapy and placebo group in reducing incidence of POAG
  • 86. EGPS  Risk factors for progression 1.Older age 2.Thinner CCT 3.Higher vertical cup disc ratio 4.Higher Pattern standard deviation
  • 87. EGPS  The role of systemic blood pressure appears important  Regression to the Mean  Minimised by multiple IOP measurements at different times of the day (diurnal variation) or on a different day.  For each mm Hg higher IOP per 12 months, the risk of converting to POAG in increased by 9% in the next 5 years.
  • 88. LOW TENSION GLAUCOMA PREVENTION STUDY  OBJECTIVE To evaluate visual field stability in low-pressure glaucoma patients randomized to intraocular pressure reduction in both eyes with topical twice daily brimonidine tartrate 0.2% versus twice daily timolol maleate 0.5%
  • 89. LOGTS  PARTICIPANTS -Low-pressure glaucoma patients - 30 years of age or older -untreated pressure of more than 21 mmHg and advanced visual field loss were excluded  Randomization of both eyes to double-masked monotherapy with brimonidine or timolol.
  • 90. LOGTS  Follow-up visits included Humphrey 24-2 full- threshold perimetry, tonometry every 4 months, and annual optic disc photography.  MAIN OUTCOME MEASURE: - Progression of visual field loss.
  • 91. LOGTS RESULTS  showed similar IOP reduction for each medication.  patients on brimonidine had less visual field loss (9.1%) compared with patients on timolol (39.2%) during an average of 30 months  28 of the 99 patients in the brimonidine arm of the study dropped out due to drug-related adverse events, compared with only 9 of the 79 timolol patients
  • 92. LOGTS RESULTS  low-pressure glaucoma patients treated with brimonidine are less likely to have field progression than patients treated with timolol  Conclusion: Brimonidine better than Timolol??
  • 93.  The study attempted to find correlations between many other baseline factors of the 2 study groups and the slower progression of glaucoma in the group that received brimonidine.  Age, sex, family history, diabetes mellitus, risk factors for low-tension glaucoma (such as migraine and the Raynaud phenomenon), and ocular perfusion pressure were investigated..
  • 94. LOGTS  Drawbacks -Data may have been skewed due to the high number of patients dropping out of the brimonidine group. -No therapeutic goal for either medication -Baseline untreated IOP was just over 15mm Hg and the mean treated IOP was around 14mm Hg
  • 95. LOGTS  For now,we should use the therapy that reduces IOP in normal-tension patients to significant levels (minimum 30%), and modify treatment if the optic nerve, retinal nerve fiber layer or visual field changes.  Prostaglandins have superb efficacy and less effect than other agents in lowering heart rate. These should be used as a first-line treatment whenever possible.
  • 96.  Remember to check blood pressure and heart rate before initiating treatment with a beta-blocker such as timolol.  Also, check if the patient is already taking a systemic beta- blocker.  Be sure that patients use timolol earlier in the evening rather than before bedtime to avoid the hypotensive effect that might compromise ocular blood flow and induce systemic hypotension.
  • 97. TAKE HOME MESSAGE In OHT cases:  Not all OHT need treatment – assess risk on individual basis and then decide  People with high risk factors may benefit from close followup and early treatment  Low risk patients can have less frequent followup and may not need early treatment.
  • 98. TAKE HOME MESSAGE In NTG cases:  Rate of progression in NTG highly variable  Only proven treatment is reducing IOP  Treat if risk factors present
  • 99. TAKE HOME MESSAGE POAG cases  Start early treatment in diagnosed cases of POAG  Choice of medical therapy first – change only if target IOP not achieved.  Surgical therapy safe  In moderate to advanced disease initial surgical therapy may be preferred
  • 100. TAKE HOME MESSAGE  Efficient patient care – practice of evidence based Rx  IOP is the main risk factor for all glaucomas  Recognize threat – lower IOP – lower risk of progression  Set a target IOP after assessing risk factors for progression

Editor's Notes

  1. 2.2 – will be revised by Pat
  2. 2.1
  3. 2.3
  4. 2.2 – will be revised by Pat
  5. Argon laser trabeculoplasty –trabeculectomy - trabeculectomy (ATT) Trabeculectomy- argon laser trabeculoplasty – trabeculectomy (TAT)